Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months

JAMA

Volumn 280, Issue 6, 1998, Pages 527-532

  Gans, Hayley A ^a   Arvin, Ann M ^a   Galinus, Jill ^a   Logan, Linda ^a   Dehovitz, Ross ^a   Maldonado, Yvonne ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MEASLES ANTIBODY; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; NEUTRALIZING ANTIBODY;

ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN EXPERIMENT; HUMORAL IMMUNE DEFICIENCY; IMMUNOGENICITY; INFANT; LYMPHOCYTE PROLIFERATION; MEASLES; MEASLES VACCINATION; NORMAL HUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SEROCONVERSION; SEROPREVALENCE; T LYMPHOCYTE SUBPOPULATION; UNITED STATES;

EID: 0032511405     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.280.6.527     Document Type: Article

References (58)

1. Clements CJ, Cutts FT. The epidemiology of measles: thirty years of vaccination. Curr Top Microbiol Immunol. 1995;191:13-33.
2. Cherry JD, Feigin RD, Lobes LA Jr.et al. Urban measles in the vaccine era: a clinical, epidemiologic, and sérologie study. J Pediatr. 1972;81:217-230.
3. Hardy GE Jr, Kassanoff I, Orbach HG, Case GE, Witte JJ. The failure of a school immunization campaign to terminate an urban epidemic of measles. Am J Epidemiol. 1970;91:2SG-293.
4. Black FL. Measles. In: Evans AS, ed. Viral Infections of Humans: Epidemiology and Control. New York, NY: Plenum Medical Book Co; 1976: 297-316.
5. Babbott FL Jr, Gordon JE. Modern measles. Am J Med Sci. 1954;228:334-361.
6. Aaby P, Clements J, Orinda V. Mortality from measles: measuring the impact. In: World Health Organization, ed. Expanded Programme on Immunization. Geneva, Switzerland:World Health Organization; 1991.
7. Gindler JS, Atkinson WL, Markowitz LE, Hutchins SS. Epidemiology of measles in the United States in 1989 and 1990. Pediatr Infect Dis J. 1992;11:841-846.
8. Krugman RD, Rosenberg R, Mclntosh K, et al. Further attenuated live measles vaccines: the need for revised recommendations. J Pediatr. 1977;91:766-767.
9. Schluederberg A, Lamm SH, Landrigan PJ, Black FL. Measles immunity in children vaccinated before one year of age. Am J Epidemiol. 1973;97:402-409.
10. Shelton JD, Jacobson JE, Orenstein WA, Schulz KF, Donnell HD Jr. Measles vaccine efficacy: influence of age at vaccination vs. duration of time since vaccination. Pediatrics. 1978;62:961-964.
11. Shasby DM, Shope TC, Downs H, Herrmann KL, Polkowski J. Epidemic measles in a highly vaccinated population. N Engl J Med. 1977;296:585-589.
12. Wilkins J, Wehrle PF. Additional evidence against measles vaccine administration to infants less than 12 months of age: altered immune response following active/passive immunization. J Pediatr. 1979;94:865-869.
13. Yeager AS, Davis JH, Ross LA, Harvey B. Measles immunization: successes and failures. JAMA. 1977;237:347-351.
14. Cherry JD. Measles. In: Feigin R, Cherry J, eds. Textbook of Pediatric Infectious Diseases. 3rd ed. Philadelphia, Pa: WB Saunders Co; 1992:1591-1609.
15. Black FL. Measles active and passive immunity in a worldwide perspective. Prog Med Virol. 1989; 36:1-33.
16. Lennon JL, Black FL. Maternally derived measles immunity in era of vaccine-protected mothers. J Pediatr. 1986;108:671-676.
17. Markowitz LE, Preblud SR, Fine PE, Orenstein WA. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J. 1990;9:101-110.
18. Pabst HF, Spady DW, Marusyk RG, et al. Reduced measles immunity in infants in a well-vaccinated population. Pediatr Infect Dis J. 1992;11:525-529.
19. Markowitz LE, Albrecht P, Rhodes P, et al, for the Kaiser Permanente Measles Vaccine Trial Team. Changing levels of measles antibody titers in women and children in the United States: impact on response to vaccination. Pediatrics. 1996;97:53-58.
20. Maldonado YA, Lawrence EC, DeHovitz R, Hartzell H, Albrecht P. Early loss of passive measles antibody in infants of mothers with vaccine-induced immunity. Pediatrics. 1995;96:447-450.
21. Bullender WM, Miller JL, Yasukawa LL, et al. Humoral and cell-mediated immunity in neonates with herpes simplex virus infection [published erratum appears in J Infect Dis. 1987;155:838]. J Infect Dis. 1987;155:28-37.
22. Pass RF, Dworsky ME, Whitley RJ, August AM, Stagno S, Alford CA Jr. Specific lymphocyte blastogenic responses in children with cytomegalovirus and herpes simplex virus infections acquired early in infancy. Infect Immun. 1981;34:166-170.
23. Hayward AR, Herberger MJ, Groothuis J, Levin MR. Specific immunity after congenital or neonatal infection with cytomegalovirus or herpes simplex virus. J Immunol. 1984;133:2469-2473.
24. Burchett SK, Corey L, Mohan KM, Westall J, Ashley R, Wilson CB. Diminished interferongamma and lymphocyte proliferation in neonatal and postpartum primary herpes simplex virus infection. J Infect Dis. 1992;165:813-818.
25. Hunt DW, Huppertz HI, Jiang HJ, Petty RE. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood. 1994;84: 4333-4343.
26. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med. 1994;180:1263-1272.
27. Brugnoni D, Airo P, Graf D, et al. Ineffective expression of CD40 ligand on cord blood T cells may contribute to poor immunoglobulin production in the newborn. Eur J Immunol. 1994;24:1919-1924.
28. Nonoyama S, Penix LA, Edwards CP, et al. Diminished expression of CD40 ligand by activated neonatal T cells. J Clin Invest. 1995;95:66-75.
29. van Essen D, Kikutani H, Gray D. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature. 1995;378:620-623.
30. Wedgwood JF, Palmer R, Weinberger B. Development of the ability to make IgG and IgA in newborns and infants. Mt Sinai J Med. 1994;61:409-415.
31. Albrecht P, Ennis FA, Saltzman EJ, Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977;91:715-718.
32. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods. 1981;3:251-260.
33. Ratnam S, Gadag V, West R, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol. 1995;33:811-815.
34. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990;162:1036-1042.
35. Johnson CE, Nalin DR, Chui LW, Whitwell J, Marusyk RG, Kumar ML. Measles vaccine immunogenidty in 6- versus 15-month-old infants born to mothers in the measles vaccine era. Pediatrics. 1994;93:939-944.
36. Measles outbreak - southwestern Utah, 1996. MMWR Morb Mortal Wkly Rep. 1997;46:766-769.
37. Atkinson WL, Hadler SC, Redd SB, Orenstein WA. Measles surveillance-United States, 1991. MMWR CDC Surveill Summ. 1992;41:1-12.
38. American Academy of Pediatrics. Measles. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, Ill: American Academy of Pediatrics; 1997: 344-357.
39. Martinez X, Brandt C, Saddallah F, et al. DNA immunization circumvents deficient induction of T helper type 1 and cytotoxic T lymphocyte responses in neonates and during early life. Proc Natl Acad Sci USA. 1997;94:8726-8731.
40. Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De Serres G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis. 1995;172:1591-1595.
41. Markowitz L, Katz S. Measles vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1994;229-276.
42. Griffin DE, Ward BJ, Esolen LM. Pathogenesis of measles virus infection: an hypothesis for altered immune responses. J Infect Dis. 1994;170(suppl 1): S24-S31.
43. Karp CL, Wysocka M, Wahl LM, et al. Mechanism of suppression of cell-mediated immunity by measles virus. Science. 1996;273:228-231.
44. Stuber E, Strober W, Neurath M. Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion. J Exp Med. 1996;183:693-698.
45. Schmitt E, Hoehn P, Huels C, et al. T helper type 1 development of naive CD4+ T cells requires the coordinate action of interleukin-12 and interferongamma and is inhibited by transforming growth factor-beta. Eur J Immunol. 1994;24:793-798.
46. Kennedy MK, Picha KS, Fanslow WC, et al. CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur J Immunol. 1996;26:370-378.
47. Ward BJ, Griffin DE. Changes in cytokine production after measles virus vaccination: predominant production of IL-4 suggests induction of a Th2 response. Clin Immunol Immunopathol. 1993;67:171-177.
48. Griffin DE. Immune responses during measles virus infection. Curr Top Microbiol Irnmunol. 1995;191:117-134.
49. Griffin DE, Ward BJ. Differential CD4 T cell activation in measles. J Infect Dis. 1993;168:275-281.
50. Hussey GD, Goddard EA, Hughes J, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J Infect Dis. 1996;173:1320-1326.
51. Oxenius A, Campbell KA, Maliszewski CR, et al. CD40-CD40 ligand interactions are criticalin T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med. 1996;183:2209-2218.
52. Klaus SJ, Berberich I, Shu G, Clark EA. CD40 and its ligand in the regulation of humoral immunity. Semin Immunol. 1994;G:279-286.
53. Siegrist CA. Potential advantages and risks of nucleic acid vaccines for infant immunization. Vaccine. 1997;15:798-800.
54. Linnemann CC Jr, Dine MS, Roselle GA, Askey PA. Measles immunity after revaccination: results . in children vaccinated before 10 months of age. Pediatrics. 1982;69:332-335.
55. Cults FT, Nyandu B, Markowitz LE, et al. Immunogenidty of high-titre AIK-C or EdmonstonZagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire. Vaccine. 1994;12:1311-1316.
56. McGraw TT. Reimmunization following early immunization with measles vaccine: a prospective study. Pediatrics. 1986;77:45-48.
57. Murphy MD, Brunell PA, Lievens AW, Shehab ZM. Effect of early immunization on antibody response to reimmunization with measles vaccine as demonstrated by enzyme-linked immunosorbent assay (ELISA). Pediatrics. 1984;74:90-93.
58. Stetler HC, Orenstein WA, Bernier RH, et al. Impact of revaccinating children who initially received measles vaccine before 10 months of age. Pediatrics. 1986;77:471-476.